Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy
Endoglin (CD105) is an accessory protein of the transforming growth factor-β receptor system expressed on vascular endothelial cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively in the contex...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2008-04, Vol.14 (7), p.1931-1937 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1937 |
|---|---|
| container_issue | 7 |
| container_start_page | 1931 |
| container_title | Clinical cancer research |
| container_volume | 14 |
| creator | DALLAS, Nikolaos A SAMUEL, Shaija LING XIA FAN FAN GRAY, Michael J LIM, Sherry J ELLIS, Lee M |
| description | Endoglin (CD105) is an accessory protein of the transforming growth factor-β receptor system expressed on vascular endothelial
cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively
in the context of this disease. The expression of endoglin is elevated on the endothelial cells of healing wounds, developing
embryos, inflammatory tissues, and solid tumors. Endoglin is a marker of activated endothelium, and its vascular expression
is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level
of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases.
Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results. |
| doi_str_mv | 10.1158/1078-0432.CCR-07-4478 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70448675</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70448675</sourcerecordid><originalsourceid>FETCH-LOGICAL-c587t-1b48afd0b14b5a56f3f6669aba75d0ebde91b9062a96c26df95253254ea3c6de3</originalsourceid><addsrcrecordid>eNpF0E1v1DAQgGELgWgp_ASQL6BySBnHXwm3KpQPqYgKLVytiTPeDWSTxU6E-u9xtAuc7MMzY-tl7LmAKyF09UaArQpQsrxqmq8F2EIpWz1g50JrW8jS6If5_tecsScp_QAQSoB6zM5EJStRSzhndzdjN22HfuSXzTsB-vVbfs0_Y_xJkU-Bb5b9FPl3TH4ZcF4icRw7fjfNNM49DnyDcUszDxltdhTxcP-UPQo4JHp2Oi_Yt_c3m-Zjcfvlw6fm-rbwurJzIVpVYeigFarVqE2QwRhTY4tWd0BtR7VoazAl1saXpgu1LrUstSKU3nQkL9ir495DnH4tlGa375OnYcCRpiU5C0pVxuoM9RH6OKUUKbhD7PcY750At6Z0aya3ZnI5pQPr1pR57sXpgaXdU_d_6tQug5cnkPPgECKOvk__XAkSoBTrBy6Pbtdvd7_7SM5nSTFSIox-54Ry1uWVQv4BIYaImA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70448675</pqid></control><display><type>article</type><title>Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>DALLAS, Nikolaos A ; SAMUEL, Shaija ; LING XIA ; FAN FAN ; GRAY, Michael J ; LIM, Sherry J ; ELLIS, Lee M</creator><creatorcontrib>DALLAS, Nikolaos A ; SAMUEL, Shaija ; LING XIA ; FAN FAN ; GRAY, Michael J ; LIM, Sherry J ; ELLIS, Lee M</creatorcontrib><description>Endoglin (CD105) is an accessory protein of the transforming growth factor-β receptor system expressed on vascular endothelial
cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively
in the context of this disease. The expression of endoglin is elevated on the endothelial cells of healing wounds, developing
embryos, inflammatory tissues, and solid tumors. Endoglin is a marker of activated endothelium, and its vascular expression
is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level
of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases.
Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-07-4478</identifier><identifier>PMID: 18381930</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>angiogenesis ; Animals ; Antigens, CD - physiology ; Antineoplastic agents ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; cancer ; CD105 ; Endoglin ; Endothelial Cells - metabolism ; Humans ; Medical sciences ; Neoplasms - blood supply ; Neoplasms - metabolism ; Neovascularization, Pathologic - physiopathology ; Pharmacology. Drug treatments ; Receptors, Cell Surface - physiology ; Transforming Growth Factor beta - metabolism ; vasculature</subject><ispartof>Clinical cancer research, 2008-04, Vol.14 (7), p.1931-1937</ispartof><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c587t-1b48afd0b14b5a56f3f6669aba75d0ebde91b9062a96c26df95253254ea3c6de3</citedby><cites>FETCH-LOGICAL-c587t-1b48afd0b14b5a56f3f6669aba75d0ebde91b9062a96c26df95253254ea3c6de3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,3343,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20300215$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18381930$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DALLAS, Nikolaos A</creatorcontrib><creatorcontrib>SAMUEL, Shaija</creatorcontrib><creatorcontrib>LING XIA</creatorcontrib><creatorcontrib>FAN FAN</creatorcontrib><creatorcontrib>GRAY, Michael J</creatorcontrib><creatorcontrib>LIM, Sherry J</creatorcontrib><creatorcontrib>ELLIS, Lee M</creatorcontrib><title>Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Endoglin (CD105) is an accessory protein of the transforming growth factor-β receptor system expressed on vascular endothelial
cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively
in the context of this disease. The expression of endoglin is elevated on the endothelial cells of healing wounds, developing
embryos, inflammatory tissues, and solid tumors. Endoglin is a marker of activated endothelium, and its vascular expression
is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level
of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases.
Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results.</description><subject>angiogenesis</subject><subject>Animals</subject><subject>Antigens, CD - physiology</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>cancer</subject><subject>CD105</subject><subject>Endoglin</subject><subject>Endothelial Cells - metabolism</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Neoplasms - blood supply</subject><subject>Neoplasms - metabolism</subject><subject>Neovascularization, Pathologic - physiopathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptors, Cell Surface - physiology</subject><subject>Transforming Growth Factor beta - metabolism</subject><subject>vasculature</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1v1DAQgGELgWgp_ASQL6BySBnHXwm3KpQPqYgKLVytiTPeDWSTxU6E-u9xtAuc7MMzY-tl7LmAKyF09UaArQpQsrxqmq8F2EIpWz1g50JrW8jS6If5_tecsScp_QAQSoB6zM5EJStRSzhndzdjN22HfuSXzTsB-vVbfs0_Y_xJkU-Bb5b9FPl3TH4ZcF4icRw7fjfNNM49DnyDcUszDxltdhTxcP-UPQo4JHp2Oi_Yt_c3m-Zjcfvlw6fm-rbwurJzIVpVYeigFarVqE2QwRhTY4tWd0BtR7VoazAl1saXpgu1LrUstSKU3nQkL9ir495DnH4tlGa375OnYcCRpiU5C0pVxuoM9RH6OKUUKbhD7PcY750At6Z0aya3ZnI5pQPr1pR57sXpgaXdU_d_6tQug5cnkPPgECKOvk__XAkSoBTrBy6Pbtdvd7_7SM5nSTFSIox-54Ry1uWVQv4BIYaImA</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>DALLAS, Nikolaos A</creator><creator>SAMUEL, Shaija</creator><creator>LING XIA</creator><creator>FAN FAN</creator><creator>GRAY, Michael J</creator><creator>LIM, Sherry J</creator><creator>ELLIS, Lee M</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080401</creationdate><title>Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy</title><author>DALLAS, Nikolaos A ; SAMUEL, Shaija ; LING XIA ; FAN FAN ; GRAY, Michael J ; LIM, Sherry J ; ELLIS, Lee M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c587t-1b48afd0b14b5a56f3f6669aba75d0ebde91b9062a96c26df95253254ea3c6de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>angiogenesis</topic><topic>Animals</topic><topic>Antigens, CD - physiology</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>cancer</topic><topic>CD105</topic><topic>Endoglin</topic><topic>Endothelial Cells - metabolism</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Neoplasms - blood supply</topic><topic>Neoplasms - metabolism</topic><topic>Neovascularization, Pathologic - physiopathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptors, Cell Surface - physiology</topic><topic>Transforming Growth Factor beta - metabolism</topic><topic>vasculature</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DALLAS, Nikolaos A</creatorcontrib><creatorcontrib>SAMUEL, Shaija</creatorcontrib><creatorcontrib>LING XIA</creatorcontrib><creatorcontrib>FAN FAN</creatorcontrib><creatorcontrib>GRAY, Michael J</creatorcontrib><creatorcontrib>LIM, Sherry J</creatorcontrib><creatorcontrib>ELLIS, Lee M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DALLAS, Nikolaos A</au><au>SAMUEL, Shaija</au><au>LING XIA</au><au>FAN FAN</au><au>GRAY, Michael J</au><au>LIM, Sherry J</au><au>ELLIS, Lee M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>14</volume><issue>7</issue><spage>1931</spage><epage>1937</epage><pages>1931-1937</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Endoglin (CD105) is an accessory protein of the transforming growth factor-β receptor system expressed on vascular endothelial
cells. Mutation of the endoglin gene is associated with hereditary hemorrhagic telangiectasias, or Osler-Weber-Rendu syndrome, and has been studied extensively
in the context of this disease. The expression of endoglin is elevated on the endothelial cells of healing wounds, developing
embryos, inflammatory tissues, and solid tumors. Endoglin is a marker of activated endothelium, and its vascular expression
is limited to proliferating cells. Recent studies identified endoglin expression in several solid tumor types, with the level
of expression correlating with various clinicopathologic factors including decreased survival and presence of metastases.
Attempts to target endoglin and the cells that express this protein in tumor-bearing mice have yielded promising results.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>18381930</pmid><doi>10.1158/1078-0432.CCR-07-4478</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2008-04, Vol.14 (7), p.1931-1937 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70448675 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | angiogenesis Animals Antigens, CD - physiology Antineoplastic agents Biological and medical sciences Biomarkers, Tumor - analysis cancer CD105 Endoglin Endothelial Cells - metabolism Humans Medical sciences Neoplasms - blood supply Neoplasms - metabolism Neovascularization, Pathologic - physiopathology Pharmacology. Drug treatments Receptors, Cell Surface - physiology Transforming Growth Factor beta - metabolism vasculature |
| title | Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A02%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endoglin%20(CD105):%20A%20Marker%20of%20Tumor%20Vasculature%20and%20Potential%20Target%20for%20Therapy&rft.jtitle=Clinical%20cancer%20research&rft.au=DALLAS,%20Nikolaos%20A&rft.date=2008-04-01&rft.volume=14&rft.issue=7&rft.spage=1931&rft.epage=1937&rft.pages=1931-1937&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-07-4478&rft_dat=%3Cproquest_cross%3E70448675%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70448675&rft_id=info:pmid/18381930&rfr_iscdi=true |